drugset
drugset / Trial / NCT02906176

Influence of SLCO2B1 Polymorphism on the PK of Voriconazole in CYP2C19 PM

NCT02906176 ↗

Phase 1 Completed 12 enrolled Seoul National University Hospital
Non-randomizedCrossoverOpen-labelBasic science

Summary

A clinical trail to investigate the influence of SLCO2B1 polymorphism on the pharmacokinetic characteristics of voriconazole in CYP2C19 poor metabolizers

Timeline

Start
2016-09
Primary completion
2016-11
Completion
2017-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Voriconazole Small molecule 200 mg Intravenous

Indications

No indication recorded.